Karin Jooss
Chief Tech/Sci/R&D Officer at GRITSTONE BIO, INC.
Net worth: 561 009 $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
J. Wolchko | M | 53 | 17 years | |
Andrew Allen | M | 57 | 9 years | |
William Rastetter | M | 75 | 13 years | |
Shefali Agarwal | M | 50 | 5 years | |
John Mendlein | M | 64 | 17 years | |
Elaine Jones | M | 69 | 5 years | |
Naiyer Rizvi | M | 60 | - | |
Robert Epstein | M | 58 | 10 years | |
Robert Hershberg | M | 61 | 4 years | |
James Cho | M | - | 5 years | |
Yuan Xu | M | 56 | 3 years | |
Clare Fisher | F | 51 | 2 years | |
Bahram Valamehr | M | 47 | 6 years | |
Erin Jones | M | 52 | 8 years | |
Cindy Tahl | F | 51 | 15 years | |
Joseph Echevarria | M | 66 | 9 years | |
Steve Krognes | M | 55 | 6 years | |
George E. MacDougall | M | - | 3 years | |
Helen Hobbs | M | 71 | 13 years | |
Edward Dulac | M | 49 | 4 years | |
Jim Smith | M | 64 | 10 years | |
Lawrence Corey | M | 77 | 2 years | |
Tim Coughlin | M | 57 | 11 years | |
Michael Lee | M | 45 | 6 years | |
Shantanu Narayen | M | 60 | 11 years | |
Bryan Supran | M | - | 8 years | |
Jerome C. Bressi | M | - | 6 years | |
Steve Danehy | M | - | 12 years | |
Jim Beitel | M | - | 7 years | |
Stacy Lea Proctor | F | - | - | |
Denis Patrick | M | - | 14 years | |
Matthew Hawryluk | M | 46 | 9 years | |
Mikael Dolsten | M | 65 | 15 years | |
Vassiliki Economides | F | 44 | 3 years | |
Wen Bo Wang | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey Kindler | M | 68 | 8 years | |
William Steere | M | 88 | 28 years | |
George A. Lorch | M | 82 | 15 years | |
Amir Nashat | M | 51 | 13 years | |
Amy Schulman | F | 63 | 6 years | |
Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
Olivier Brandicourt | M | 68 | 13 years | |
Everett Cunningham | M | 57 | 9 years | |
Peter Svennilson | M | 62 | 4 years | |
John Mascotte | M | 84 | 4 years | |
Thomas Woiwode | M | 52 | 6 years | |
Robert Landry | M | 60 | 4 years | |
Richard Heyman | M | 66 | 7 years | |
Marc Tessier-Lavigne | M | 64 | 4 years | |
Yi Ning Zhao | M | 53 | 8 years | |
Judith Li | F | 40 | 5 years | |
Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
Dana George Mead | M | 88 | 12 years | |
Nicholas Simon | M | 67 | 6 years | |
Michael Brown | M | 83 | 16 years | |
M. Anthony Burns | M | 81 | 25 years | |
William Herbert Gray | M | 82 | 13 years | |
Robert N. Burt | M | 86 | 11 years | |
Frances Fergusson | M | 79 | 9 years | |
Freda Lewis-Hall | M | 69 | 11 years | |
John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
John Porter | M | 53 | 5 years | |
Joann Eisenhart | M | 65 | 12 years | |
Randy Brenner | M | 51 | 15 years | |
François-Maurice Garnier | M | 62 | - | |
Cara Cassino | M | 62 | 5 years | |
Thomas Liquard | M | 51 | 4 years | |
Michael Bruce | M | - | 12 years | |
Timothy Sullivan | M | 54 | 2 years | |
Richard Buller | M | 74 | 7 years | |
Margaret McLoughlin | M | 60 | 5 years | |
Robyn Peters | F | - | 4 years | |
Valerie L. Legagneur | F | 50 | 10 years | |
Feng Guo | M | 54 | 11 years | |
Susan E. Ward | M | - | 2 years | |
Glenn Miles | M | 58 | 4 years | |
Brian Krex | M | 57 | 9 years | |
David Roth | M | 61 | 4 years | |
David Simmons | M | 59 | 16 years | |
Aaron H. Burstein | M | - | 11 years | |
Edmund Harrigan | M | 71 | 12 years | |
Neil Gibson | M | 67 | 4 years | |
Jennifer J. Rhodes | F | 53 | 6 years | |
Charles A. Baker | M | 91 | 19 years | |
Corey Goodman | M | 72 | 2 years | |
Scott R. Shively | M | 67 | 3 years | |
Angela Rossetti | F | 71 | 5 years | |
Peter Honig | M | 67 | 7 years | |
Peter H. Reinhart | M | - | 6 years | |
John Thompson | M | 57 | 7 years | |
Marc Stapley | M | 54 | 3 years | |
Howard Mayer | M | 61 | 7 years | |
Christine Regan Lindenboom | F | 43 | - | |
Brenda Mitchell | F | - | - | |
Anja Guntermann | M | - | 9 years | |
Julie LeChasseur | F | - | 4 years | |
Lillian Mu | F | - | 4 years | |
Michael Pastoor | M | - | 5 years | |
Anna Berkenblit | M | 54 | 4 years | |
James Wassil | M | 54 | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karin Jooss
- Personal Network